# MRI-based biomarkers for risk stratification and assessment of treatment response in Metabolic dysfunction-associated Steatotic liver disease

- **DOI:** [10.1097/hep.0000000000001908](https://doi.org/10.1097/hep.0000000000001908)
- **Rating:** Strong (3.8 out of 5)
- **Verdict:** A clinically useful synthesis separates MRI biomarkers' diagnostic and surrogate-endpoint roles, but undocumented source selection limits confidence in evidence completeness.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-04
- **Evaluation page:** https://www.nabu.science/paper/10.1097%2Fhep.0000000000001908

## Key claims

1. MRI proton density fat fraction (MRI-PDFF) is the most accurate noninvasive measure of steatosis (thresholds of 6.4%, 17.4% and 22.1% for grades ≥1, ≥2 and 3), and a ≥30% relative reduction is associated with histologic response.
   - Support: Supported
   - Type: Primary finding
   - Basis: heterogeneous biopsy-validation cohorts and small treatment trials support diagnostic accuracy and histologic-response associations
   - Location: Abstract, MRI-PDFF summary sentence
2. Liver stiffness by magnetic resonance elastography (MRE-LS) is the most accurate imaging biomarker for fibrosis
   - Support: Supported
   - Type: Secondary
   - Basis: prospective and pooled biopsy comparisons favor MRE, although head-to-head confidence intervals overlap
   - Location: Abstract; Key Points
3. The risk of hepatic decompensation rises by 43% for each 1-kPa increase in MRE-LS.
   - Support: Well-supported
   - Type: Secondary
   - Basis: six-cohort individual-participant meta-analysis with 119 events directly supports the stated association
   - Location: Key Points, fourth bullet
4. Iron-corrected T1 is a sensitive but nonspecific marker of disease activity whose prognostic value requires further study.
   - Support: Supported
   - Type: Secondary
   - Basis: variable diagnostic validation and event-limited outcome cohorts support the nonspecific characterization and explicit prognostic uncertainty
   - Location: Abstract, cT1 summary sentence
5. MRE is cost-effective compared with vibration-controlled transient elastography for detecting advanced fibrosis.
   - Support: Tentative
   - Type: Secondary
   - Basis: selected US and Canadian economic models do not establish unrestricted cost-effectiveness across health systems
   - Location: Abstract, MRE cost-effectiveness sentence

## Strengths

- **Prospective validation receives explicit interpretive priority** The review contrasts derivation estimates with prospective LITMUS findings and gives external validation greater weight. Tables expose lower validation performance rather than presenting only favorable estimates.
  - Dimension: methodological rigour
  - Location: Comparative-performance LITMUS discussion; Tables 1–2
- **Biomarker roles remain distinct throughout synthesis** Diagnostic accuracy, pharmacodynamic response, prognostic association, and surrogate-endpoint qualification are treated as different evidentiary questions. This distinction clarifies what current MRI evidence supports and what remains unestablished.
  - Dimension: contribution
  - Location: MRI-PDFF section; cT1 section; regulatory section
- **Regulatory requirements connect evidence to next steps** The review maps MRE evidence against the FDA's three surrogate-endpoint considerations and distinguishes acceptance of a letter of intent from qualification. Missing outcome-linked change thresholds are explicitly identified.
  - Dimension: positioning
  - Location: Imaging Biomarkers in Clinical Trials – Regulatory Considerations and Unmet Need

## Limitations

- **Source selection lacks a reported method** No search strategy, eligibility criteria, or source-selection account accompanies the comparative synthesis. Readers cannot assess completeness despite the visible engagement with contrary evidence.
  - Dimension: methodological rigour
  - Location: Full text, including Introduction and review sections
- **Abstract economics exceed the supporting settings** The abstract states MRE cost-effectiveness without qualification, while the supporting economic models concern selected US and Canadian pathways. The body acknowledges that capacity and reimbursement can make those conclusions inapplicable elsewhere.
  - Dimension: reporting
  - Location: Abstract; Cost Effectiveness for Identifying Advanced Fibrosis and Availability
- **Clinical benefit thresholds remain prospectively unestablished** Treatment-induced imaging changes have not been linked to clinical benefit through established prospective thresholds. Existing diagnostic validation therefore does not establish readiness to replace clinical outcomes with imaging surrogate endpoints.
  - Dimension: application pathway
  - Location: Imaging Biomarkers in Clinical Trials – Regulatory Considerations and Unmet Need; Future Directions

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted. One reported value does not reconcile, but the key claims do not rest on it.
  - Minor reporting notes (1):
    - Descriptive: "The highest AUC for at-risk MASH overall was achieved by the serum biomarker NIS2+ (0.82, 95% CI 0.77–0.88), although it also did not meet the criterion" (Quantitative Assessment of Liver Fibrosis, comparative-performance section, LITMUS paragraph) vs "In the prospective LITMUS study with a prespecified minimum acceptable AUC of 0.80" (Quantitative Assessment of Liver Fibrosis, comparative-performance section, LITMUS paragraph). NIS2+ has a point-estimate AUC above 0.80 but a lower confidence bound below 0.80, so the reported failure requires an acceptance rule beyond the stated point-estimate threshold. → Effect on result unclear
- **Reporting and transparency:** Noted. Table 5 assigns the denifanstat trial the wrong reference number. Financial interests and funding are explicitly disclosed.
  - Conflict of interest: declared
- **Reference integrity:** Clean. 157 of 157 checkable references verified
  - 167 references in manuscript
  - 10 have no canonical index record — counted, but not index-checkable
  - 1 reference confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-04